Takeda

A public company • NYSE: TAK TYO: 4502

Cambridge, Massachusetts, USA

https://www.takeda.com/en-us/

Research

Andrew S. Plump

President, Research & Development

Christophe Weber

President & CEO

Costa Saroukos

Chief Financial Officer

Gerard Greco

Global Quality Officer

Giles Platford

President, Europe & Canada Business Unit

Marcello Agosti

Global Business Development Officer

Masato Iwasaki

President, Japan Pharma Business Unit

Milano Furuta

Corporate Strategy Officer & Chief of Staff

Ramona Sequeira

President, U.S. Business Unit and Global Portfolio Commercialization

Takako Ohyabu

Chief Global Corporate Affairs Officer

Teresa Bitetti

President, Global Oncology Business Unit

Thomas Wozniewski

Global Manufacturing & Supply Officer

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

Completed

Ketamine-Induced Brain Activity Changes

Psychotic-like Symptoms

Start Date: Aug 2013

Last Updated: Nov 2016

Salt Lake City, Utah, USA

Ketamine

A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

Completed

Healthy Volunteers

Start Date: Feb 2019

Last Updated: Mar 2021

Leiden, South Holland, Netherlands

Ketamine

Efficacy and Safety of TAK-653 in Treatment-Resistant Depression

Withdrawn

Treatment-Resistant Depression

Start Date: Feb 2018

Last Updated: Feb 2018

Ketamine

A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

Completed

Healthy Volunteers

Start Date: Feb 2019

Last Updated: Mar 2021

Leiden, South Holland, Netherlands

Ketamine

Related Organizations:

Douglas Pharmaceuticals Limited

EntheogeniX

Field Trip Health

Organic Flower

Otsuka

Toronto Center for Psychedelic Science

Takeda

People

Clinical Trials

Related Organizations: